Martijn Gerritsen

Martijn Gerritsen

Auto-generated profile, based on publicly available information

Martijn Gerritsen

Amsterdam Rheumatology and Immunology Center

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
DVDaisy Vedder
Daisy Vedder
WWWendy Walrabenstein
Wendy Walrabenstein
MHMaaike Heslinga
Maaike Heslinga
RVRalph de Vries
Ralph de Vries
MNM.T. Nurmohamed
M.T. Nurmohamed
MGMartijn Gerritsen
Martijn Gerritsen
Gout is one of the most prevalent inflammatory rheumatic disease. It is preceded by hyperuricemia and associated with an increased risk for cardiovascular disease, both related to unhealthy diets. The objective of this systematic review is to better define the most appropriate diet addressing both disease activity and traditional cardiovascular risk factors in hyperuricemic patients. We included clinical trials with patients diagnosed with hyperuricemia or gout, investigating the effect of dietary interventions on serum uric acid (SUA) levels, gout flares and—if available—cardiovascular risk factors. Eighteen articles were included, which were too heterogeneous to perform a meta-analysis. Overall, the risk of bias of the studies was moderate to high. We distinguished four groups of dietary interventions: Calorie restriction and fasting, purine-low diets, Mediterranean-style diets, and supplements. Overall, fasting resulted in an increase of SUA, whilst small (SUA change +0.3 to −2.9 mg/dL) but significant effects were found after low-calorie, purine-low, and Mediterranean-style diets. Studies investigating the effect on cardiovascular risk factors were limited and inconclusive. Since Mediterranean-style diets/DASH (Dietary Approach to Stop Hypertension) have shown to be effective for the reduction of cardiovascular risk factors in other at-risk populations, we recommend further investigation of such diets for the treatment of gout.

5 October 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
JKJesper Knoop
Jesper Knoop
JDJoost Dekker
Joost Dekker
JKJan-Paul Klein
Jan-Paul Klein
MLMarike van der Leeden
Marike van der Leeden
MEMartin van der Esch
Martin van der Esch
WLWillem F Lems
Willem F Lems
Introduction: We aimed to explore the associations between knee osteoarthritis (OA)-related tissue abnormalities assessed by conventional radiography (CR) and by high-resolution 3.0 Tesla magnetic resonance imaging (MRI), as well as biomechanical factors and findings from physical examination in patients with knee OA. Methods: This was an explorative cross-sectional study of 105 patients with knee OA. Index knees were imaged using CR and MRI. Multiple features from CR and MRI (cartilage, osteophytes, bone marrow lesions, effusion and synovitis) were related to biomechanical factors (quadriceps and hamstrings muscle strength, proprioceptive accuracy and varus-valgus laxity) and physical examination findings (bony tenderness, crepitus, bony enlargement and palpable warmth), using multivariable regression analyses. Results: Quadriceps weakness was associated with cartilage integrity, effusion, synovitis (all detected by MRI) and CR-detected joint space narrowing. Knee joint laxity was associated with MRI-detected cartilage integrity, CR-detected joint space narrowing and osteophyte formation. Multiple tissue abnormalities including cartilage integrity, osteophytes and effusion, but only those detected by MRI, were found to be associated with physical examination findings such as crepitus. Conclusion: We observed clinically relevant findings, including a significant association between quadriceps weakness and both effusion and synovitis, detected by MRI. Inflammation was detected in over one-third of the participants, emphasizing the inflammatory component of OA and a possible important role for anti-inflammatory therapies in knee OA. In general, OA-related tissue abnormalities of the knee, even those detected by MRI, were found to be discordant with biomechanical and physical examination features.

5 April 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
LBLaura Boekel
Laura Boekel
FHFemke Hooijberg
Femke Hooijberg
EVErik H Vogelzang
Erik H Vogelzang
YBYaëlle R Besten
Yaëlle R Besten
MLMaureen Leeuw
Maureen Leeuw
GWGertjan Wolbink
Gertjan Wolbink
Background Research on the disease severity of COVID-19 in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) has been inconclusive, and long-term prospective data on the development of SARS-CoV-2 antibodies in these patients are lacking. Methods Adult patients with rheumatic IMIDs from the Amsterdam Rheumatology and Immunology Center, Amsterdam were invited to participate. All patients were asked to recruit their own sex-matched and age-matched control subject. Clinical data were collected via online questionnaires (at baseline, and after 1–4 and 5–9 months of follow-up). Serum samples were collected twice and analysed for the presence of SARS-CoV-2-specific antibodies. Subsequently, IgG titres were quantified in samples with a positive test result. Findings In total, 3080 consecutive patients and 1102 controls with comparable age and sex distribution were included for analyses. Patients were more frequently hospitalised compared with controls when infected with SARS-CoV-2; 7% vs 0.7% (adjusted OR: 7.33, 95% CI: 0.96 to 55.77). Only treatment with B-cell targeting therapy was independently associated with an increased risk of COVID-19-related hospitalisation (adjusted OR: 14.62, 95% CI: 2.31 to 92.39). IgG antibody titres were higher in hospitalised compared with non-hospitalised patients, and slowly declined with time in similar patterns for patients in all treatment subgroups and controls. Interpretation We observed that patients with rheumatic IMIDs, especially those treated with B-cell targeting therapy, were more likely to be hospitalised when infected with SARS-CoV-2. Treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs other than B-cell targeting agents is unlikely to have negative effects on the development of long-lasting humoral immunity against SARS-CoV-2.

23 August 2022 in The Lancet Rheumatology
Verified
Journal Article
Open access
LBLaura Boekel
Laura Boekel
YBYaëlle R Besten
Yaëlle R Besten
FHFemke Hooijberg
Femke Hooijberg
RWRosa Wartena
Rosa Wartena
MSMaurice Steenhuis
Maurice Steenhuis
GWGertjan Wolbink
Gertjan Wolbink

17 January 2025 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
RSRd Stultz
Rd Stultz
LDL Dai
L Dai
EGE van Geel
E van Geel
MGM Gerritsen
M Gerritsen
MNM.T. Nurmohamed
M.T. Nurmohamed
CLChristian Lood
Christian Lood
Although gout is the most common inflammatory arthritis, there are few tools to monitor disease activity and predict complications in gout patients. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) are associated with disease activity in various diseases and the NLR has been shown to predict coronary artery disease severity, a common comorbid condition with gout. Thus, we evaluated the use of NLR and MLR as novel biomarkers to measure disease activity and predict cardiovascular disease (CVD) risk in gout patients. Data were collected from 38 gout patients. Disease activity, including total number of acute gout attacks, and 10 year risk of cardiovascular morbidity, were assessed at the patient's visit. Calprotectin, cell counts, and uric acid levels were measured from patients' blood. Levels of the neutrophil activation marker calprotectin correlated with NLR (r = 0.56, p = 0.0004). MLR correlated with total number of gout attacks as well (r = 0.39, p = 0.02). NLR and MLR, but not absolute monocyte or neutrophil counts, were significantly correlated with body mass index and significantly increased in gout patients with high CVD risk (p < 0.05). Using logistic regression analysis, patients with high NLR or MLR (defined as the upper quartile of patients) had increased odds of developing high CVD risk (odds ratio 7.5, 95% confidence interval 1.7-33.0). NLR and MLR are potential biomarkers to predict gout flare risk. An increase in either may indicate an increased risk of CVD morbidity.